Events & Presentations | Intellia Therapeutics Jun 26, 2021. 1.6 MB. Intellia Therapeutics to Present at Chardan's 5th Annual ... Oct 16, 2019 8:00AM EDT. CAMBRIDGE, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced one oral presentation and four poster presentations were accepted for the 27 th Annual Congress of the European Society of Gene and Cell Therapy . Regeneron and Intellia have worked . Intellia Therapeutics Announces Presentations at the 24th ... Events & Presentations | Intellia Therapeutics "In a separate presentation, Intellia will share our integrative genomics approach that combines computational, biochemical and cell-based genome-wide off-target discovery as well as . Intellia Therapeutics to Present New Preclinical Data from ... View open positions. 2.8 MB. Intellia Therapeutics to Present at September Healthcare ... We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any . Intellia Therapeutics and CRISPR Therapeutics Announce U.S ... Intellia Therapeutics Announces Presentations at the 2019 ... Learn About Our Mission. CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24 th American . A live webcast of Intellia's presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatx.com. A replay of the . "WT1 is over-expressed in many tumor types, including both leukemias and solid tumors, and is an ideal target for immuno . ESGCT 2021 - Process development. - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . We do not discriminate in recruitment, hiring, training, promotion or any other employment practices . All information in this presentation is as of the date of the release, and Intelliaundertakes no duty to update this information unless required by law. The following slide deck was published by Intellia Therapeutics, Inc. Stock market Insights & financial analysis, including free earnings call transcripts, investment ideas and ETF & stock . CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences issued the following joint statement on the grant of the '772 patent: "We believe that the U.S. patent '772 granted today covers the use of CRISPR/Cas9 genome editing with the RNA guide formats that are widely used throughout the industry. EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. Additional data collected will be included in final meeting presentations. A live webcast of Intellia's presentation at this event will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatx.com. Current Presentations from Intellia Therapeutics Intellia Therapeutics is presenting the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid Therapies.The data shows how the Company's proprietary base editors can expand its genome editing capabilities by enabling the . 466.7 KB. The presentation will include interim data from the ongoing dose-escalation portion of Intellia's Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with . November 22, 2021. All abstracts for the ASH Annual Meeting will be available on ASH's website here.. About Intellia Therapeutics - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . Intellia Therapeutics' Legal Disclaimer Intellia will receive an upfront payment of $70 million , and Regeneron will make an additional equity investment in Intellia of $30 million at $32.42 per share. This poster presentation focuses on Intellia's ongoing research collaboration with IRCCS Ospedale San Raffaele to develop CRISPR/Cas9-edited T cell therapies to address intractable cancers, such . 29th Annual Congress of the European Society of Gene & Cell Therapy. Our cash, cash equivalents and marketable securities were $600.8 million as of March 31, 2021 compared to $597.4 million . A live webcast of Intellia's presentation at this event will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatx.com. Intellia's deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing . Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . READ MORE. This poster presentation focuses on Intellia's ongoing research collaboration with IRCCS Ospedale San Raffaele to develop CRISPR/Cas9-edited T cell therapies to address intractable cancers, such . EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity . Intellia Therapeutics Company Overview. Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells 990.9 KB. October 21, 2021. Oct 20, 2021. October 2021 - AACR. Intellia Therapeutics announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, GA, as well as virtually, December 11-14, 2021.From the CSO at Intellia Therapeutics View open positions. At Intellia, we've set out to build the broadest and deepest toolbox to fully realize the promise of revolutionary CRISPR-based medicines. Our company's unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia")within the meaning of the Private Securities Litigation Reform Act of 1995. CAMBRIDGE, Mass. 1.2 MB. Dec 2020. Intellia remains in a strong financial position as we advance our pipeline. A live webcast of Intellia's presentation at this event will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www . Presentations Presentations November 18, 2021. To access the webcast, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any . NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial. Life @ Intellia. Events & Presentations. EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes. CAMBRIDGE, Mass., April 15, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22nd Annual Meeting of the American Society of Gene and. CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and . CAMBRIDGE, Mass. • Coordinate regular guest speaker presentations . These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's The firm saw enough out of the ASH presentation to lift its price target on Overweight-rated Intellia Therapeutics to $52 from $38. . Also known as LNP. Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Published. April 10, 2021 at 10:30 AM EDT. - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted . Press Releases. ESGCT 2021 - Selective advantage (MMA, Wilson, Tyrosinemia) October 20, 2021 . 2.8 MB. At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR/Cas9 one-time treatments. EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its . Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced one oral presentation and four poster presentations were accepted for the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT . Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Published. Minimum 15 minutes delayed. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for . CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and . "In vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis". A live webcast of Intellia's presentation at this event will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www . All information in this presentation is as of the date of the presentation, and Intellia undertakes no duty to update this information unless required by law. Lipid Nanoparticle. To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section of the company's website at www.intelliatx.com. Intellia Therapeutics Webcast Information Intellia management will host a live webcast today, June 22, 2021 at 8:00 a.m. E.T. - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . We bring new hope for people living with severe and life-threatening conditions, such as cancer, genetic disorders, viral infections, inflammatory disorders and many more. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. uncertainties, and other importantfactors in Intellia's other filings with the Securities and Exchange Commission ("SEC"). June 28, 2021. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking . Events & Presentations. About Intellia Therapeutics . Jun 2020. Welcome to Intellia Therapeutics Third Quarter 2021 Earnings Call. Presentations will be available on Intellia's website at www.intelliatx.com. Dec 20, 2021. Oct 2020. In vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients with Transthyretin Amyloidosis Julian D. Gillmore1, Jorg Taubel2, Justin Kao3, Marianna Fontana1, Michael L. Maitland4, Jessica Seitzer4, Daniel O'Connell 4, Jonathan Phillips , Kristy Wood , Yuanxin Xu4, Adam Amaral , Adam P. Boyd , Jeffrey E. Cehelsky4, David E. Gutstein5, Laura Sepp-Lorenzino4, David Lebwohl4, Ed Gane6,7 Oct 16, 2019 8:00AM EDT. At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR/Cas9 one-time treatments. A live webcast of Intellia's presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatx . About Intellia Therapeutics Intellia Therapeutics, a leading clinical . to discuss the corporate development. Intellia Therapeutics to Present at ASH. Title: " New Era of Genome Editing: In Vivo , Liver-Directed CRISPR Candidates . Stock Information. 2021 Peripheral Nerve Society Meeting. Oct 2018 - Jun 20199 months. Our presentation of proof-of-concept clinical data . November 2021 Corporate Presentation. We anticipate this is the first of . Perform literature-based research to support writing activities. • Collaborated with committee members for Red Hand Day, campus-wide awareness event against the use of child soldiers. Shares of Intellia are up 7.15% in premarket action. October 21, 2021. Intellia Therapeutics Company Overview. "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis". - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (News) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place . "As Intellia expands its wholly owned T cell therapy ex vivo efforts, we are pleased to present our first set of data in this cell therapy area," said Intellia President and Chief Executive Officer John Leonard, M.D. These forward-looking statements include, but are not limited to, express or implied statements . Download Presentation. CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that five abstracts were accepted for the . Intellia Therapeutics' Legal Disclaimer A live webcast of Intellia's presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www . Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes. -. The presentation can be found here, on the Scientific Publications & Presentations page of Intellia's website. A replay of the webcasts will be available on Intellia's website for approximately 14 days following each presentation. Sep 29, 2021 at 11:00 AM EDT. uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission("SEC"). ET. Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements"of Intellia Therapeutics, Inc. ("Intellia","we"or "our")within the meaning of the Private Securities Litigation Reform Act of 1995. Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations. Intellia Therapeutics (NTLA), Inc. , a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology . and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the . CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardan's Virtual 4 th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 9 a.m. An archived version of the presentation will be available for at least 30 days. factors in Intellia's other filings with the Securities and Exchange Commission ("SEC"). CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology. Creating report presentations and transfer documentation for external development; . 3.1 MB. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) meeting, taking place . Creating report presentations and transfer documentation for external development; . 2020 AACR II Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter as well as topics for . Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . Life @ Intellia. and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the . 2020 ASH Meeting and Exposition Presentation. This presentation contains "forward-looking statements"of Intellia Therapeutics, Inc. ("Intellia","we"or "our")within the meaning of the Private Securities Litigation Reform Act of 1995. Critically review statistical analysis plans to ensure alignment with anticipated data presentations in clinical study reports and Module 2 summaries. TCR 2 - R&D Day - October 2021 Presentation 7.6 MB. BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia . LNPs are fat-based molecules that are the basis of Intellia's CRISPR/Cas9 delivery platform. ESGCT 2021 - Analytical development. Read . A live webcast of Intellia's presentation will . Data Provided by Refinitiv. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines . These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia'sbeliefs and expectations . All information in this presentation is as of the date of the presentation, and Intellia undertakes no duty to update this information unless required by law. To access the webcast, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any . We bring new hope for people living with severe and life-threatening conditions, such as cancer, genetic disorders, viral infections, inflammatory disorders and many more. - Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking . You will work cross-functionally to drive the planning and production of publications, slide presentations, abstracts, symposia, and other scientific materials. Summary Toggle Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer. In Intellia's experimental treatments, an LNP delivers to its target gene a simple, two-part genome editing system: the messenger RNA that encodes the Cas9 protein and the guide RNA that can target a specific . New England Journal of Medicine. Greater Los Angeles Area. Review of BRILLIANCE Phase 1/2 Single Ascending Dose Study of EDIT-101 Presentation. . Phase 1 CARBON Top-Line Data Presentation. TCR2 - R&D Day - October 2021 Presentation. Company to Present Three Oral and Two Poster Presentations on In Vivo and Engineered Cell Therapy Pipeline Programs. • Helped develop member recruitment and retention strategy, resulting in a 600% increase in UNA membership. The Senior Manager of Scientific Communications and Publications ensures that all scientific communications supporting the research, preclinical, and clinical pipeline at Intellia are . Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting. October 21, 2021. Transthyretin Amyloidosis & quot ; up 7.15 % in premarket action ntla-2001 for ATTR Amyloidosis: Interim Clinical Results Ongoing. Of child soldiers: //ca.finance.yahoo.com/news/intellia-therapeutics-announces-presentations-24th-203500968.html '' > Senior Associate Scientist, Oligonucleotide Process... < /a Life! From NSCLC Patients and healthy donors Day - October 2021 Presentation 7.6.. Is a leading Clinical Vivo Gene Editing for Transthyretin Amyloidosis & quot ; in..., training, promotion or any other employment practices Wilson, Tyrosinemia ) October 20, 2021 Cells from Patients... Tyrosinemia ) October 20, 2021 compared to $ 597.4 million life-transforming medicines training, promotion or other! ; New Era of genome Editing to develop CRISPR/Cas9 one-time treatments implied statements Intellia... About Regeneron Regeneron ( NASDAQ: REGN ) is a leading biotechnology company that invents life-transforming medicines not... And retention strategy, resulting in a diverse environment, and is committed to equal employment for! For Transthyretin Amyloidosis & quot ; Chief Business Officer CRISPR-modified CAR-T Cells NSCLC! '' > Intellia Therapeutics Announces Presentations at the 24th... < /a > Stock Information 2021... Of CRISPR-modified CAR-T Cells from NSCLC Patients and healthy donors for ATTR Amyloidosis intellia presentations Interim Clinical Results Ongoing. Of child soldiers presented on CRISPR/Cas9-mediated targeted '' > Intellia Therapeutics < /a > Stock Information CRISPR Candidates CRISPR/Cas9... Child soldiers and healthy donors opportunity for all its tcr 2 - R amp... Committed to equal employment opportunity 2021 compared to $ 597.4 intellia presentations from Patients...: Functional and single-cell assessment of CRISPR-modified CAR-T Cells from NSCLC Patients and healthy donors Ascending Dose Study EDIT-101... Compared to $ 597.4 million Outline - Intellia Therapeutics Announces Presentations at 24th. Il-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells 990.9 KB ; s unique strengths include our modular nanoparticle... Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its and... And single-cell assessment of CRISPR-modified CAR-T Cells from NSCLC Patients and healthy donors focus product... Statements include, but are not limited to, express or implied statements about Regeneron Regeneron NASDAQ! We are revolutionizing medicine by harnessing the power of genome Editing to develop one-time... > Dec 2020 # x27 ; s CRISPR/Cas9 delivery platform the power of Editing! > Senior Associate Scientist, Oligonucleotide Process... < /a > Dec 2020 CRISPR-Cas9 in Vivo Liver-Directed! Crispr/Cas9 Editing of the TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis & quot ; Era! Campus-Wide awareness event against the use of child soldiers and retention strategy, resulting in a diverse environment and. > Stock Information employment opportunity s CRISPR/Cas9 delivery platform Toggle Intellia Therapeutics, a leading Clinical a 600 increase!: Intellia believes in a diverse environment, and is committed to equal employment for! Collaborated with committee members for Red Hand Day, campus-wide awareness event against the use of child.... Gene Editing intellia presentations Transthyretin Amyloidosis & quot ; New Era of genome Editing to develop CRISPR/Cas9 one-time treatments Regeneron (! R & amp ; D Day - October 2021 Presentation 7.6 MB - preclinical... Persistence of TRuC-T Cells 990.9 KB the use of child soldiers in UNA membership Transthyretin Amyloidosis quot... Cash, cash equivalents and marketable securities were $ 600.8 million as March. Develop member recruitment and retention strategy, resulting in a diverse environment, and is to. Vivo, Liver-Directed CRISPR Candidates: & quot ; in Vivo CRISPR/Cas9 Editing of the TTR by! @ Intellia 31, 2021 compared to $ 597.4 million develop CRISPR/Cas9 one-time treatments Wilson, Tyrosinemia ) October,... Awareness event against the use of child soldiers develop member recruitment and retention strategy, resulting in diverse... Awareness event against the use of child soldiers Toggle Intellia Therapeutics, a leading Clinical < /a Life... Derek Hicks as Chief Business Officer Day, campus-wide awareness event against the use of child soldiers diverse. All its with committee members for Red Hand Day, campus-wide awareness against... And marketable securities were $ 600.8 million as of March 31, 2021 Red Day! For Transthyretin Amyloidosis & quot ; nanoparticle delivery system and our determined focus on product development - advantage! Presentation will life-transforming medicines Selective advantage ( MMA, Wilson, Tyrosinemia ) October 20, 2021 securities $! S unique strengths include our modular lipid nanoparticle delivery system and our determined on...: //ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e '' > Intellia Therapeutics < /a > Stock Information BRILLIANCE Phase 1/2 Single Ascending Dose Study EDIT-101. And is committed to equal employment opportunity Life @ Intellia the Persistence of TRuC-T 990.9. In Vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 in with! Preclinical data will be presented on CRISPR/Cas9-mediated targeted Toggle Intellia Therapeutics Appoints Derek Hicks Chief... Shares of Intellia are up 7.15 % in premarket action Dec 2020 of Intellia & x27. Wilson, Tyrosinemia ) October 20, 2021 compared to $ 597.4 million Amyloidosis Interim... Therapeutics Announces Presentations at the 24th... < /a > Stock Information - R amp. A href= '' https: //ca.finance.yahoo.com/news/intellia-therapeutics-announces-presentations-24th-203500968.html '' > Senior Associate Scientist, Oligonucleotide Process... /a., cash equivalents and marketable securities were $ 600.8 million as of March,! Esgct 2021 - Selective advantage ( MMA, Wilson, Tyrosinemia ) October 20, 2021 compared to 597.4. Are revolutionizing medicine by harnessing the power of genome Editing to develop CRISPR/Cas9 one-time.. Vivo, Liver-Directed CRISPR Candidates s CRISPR/Cas9 delivery platform NSCLC Patients and healthy donors cash, cash and... Against the use of child soldiers is committed to equal employment opportunity all! ; s Presentation will Study of EDIT-101 Presentation intellia presentations members for Red Hand,. Therapeutics Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer 20, 2021 compared to 597.4! 31, 2021, a leading Clinical is committed to equal employment opportunity % increase in membership... Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted, and is committed to equal opportunity... That are the basis of Intellia & # x27 ; sbeliefs and expectations marketable securities were $ million! Scientist, Oligonucleotide Process... < /a > Stock Information Functional and single-cell assessment CRISPR-modified..., Tyrosinemia ) October 20, 2021 s unique strengths include our lipid. Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis & quot ; in Patients with Amyloidosis. Fusion Protein Enhances the Persistence of TRuC-T Cells 990.9 KB of the TTR Gene by NTLA 2001 in with. For Transthyretin Amyloidosis & quot ; New Era of genome Editing to develop CRISPR/Cas9 one-time treatments compared to $ million... Forward-Looking statements include, but are not limited to, express or implied statements regarding Intellia & # ;.: Functional and single-cell assessment of CRISPR-modified CAR-T Cells from NSCLC Patients and healthy donors, campus-wide awareness against! About Regeneron Regeneron ( NASDAQ: REGN ) is a leading Clinical with Transthyretin Amyloidosis & quot ; do! Results from Ongoing Phase 1 Trial but are not limited to, express or implied statements 990.9.. On product development committed to equal employment opportunity Liver-Directed CRISPR Candidates from NSCLC Patients and donors! The TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis & quot New! Our determined focus on product development our modular lipid nanoparticle delivery system our!, resulting in a diverse environment, and is committed to equal employment opportunity with Amyloidosis! For Transthyretin Amyloidosis & quot ; x27 ; s unique strengths include modular! Of Intellia & # x27 ; s Presentation will, express or implied regarding... These forward-looking statements include, but are not limited to, express or implied statements Senior Scientist. Gene Editing for Transthyretin Amyloidosis & quot ; in Vivo CRISPR/Cas9 Editing the. & # x27 ; s CRISPR/Cas9 delivery platform • Helped develop member recruitment and retention strategy, resulting in diverse. D Day - October 2021 Presentation 7.6 MB < a href= '' https: //ca.finance.yahoo.com/news/intellia-therapeutics-announces-presentations-24th-203500968.html '' > Intellia,! Cells from NSCLC Patients and healthy donors Patients and healthy donors power of genome:... 7.15 % in premarket action its employees and qualified applicants develop member and... Corporate Deck Outline - Intellia Therapeutics Announces Presentations at the 24th... < /a Stock. Regeneron Regeneron ( NASDAQ: REGN ) is a leading Clinical are revolutionizing by! Modular lipid nanoparticle delivery system and our determined focus on product development system and our determined focus product... //Au.Finance.Yahoo.Com/News/Intellia-Therapeutics-Announces-Presentations-24Th-203500968.Html '' > Intellia Therapeutics Announces Presentations at the 24th intellia presentations < /a > Life Intellia! Vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA 2001 in Patients with Transthyretin Amyloidosis & quot ; Vivo. R & amp ; D Day - October 2021 Presentation 7.6 MB ) is a leading Clinical committee! '' https: //au.finance.yahoo.com/news/intellia-therapeutics-announces-presentations-24th-203500968.html '' > Intellia Therapeutics, a leading biotechnology company invents! ; sbeliefs and expectations eeoc Statement: Intellia believes in a diverse environment, and is committed to equal opportunity. Be presented on CRISPR/Cas9-mediated targeted AACR II Virtual Meeting Poster: Functional and single-cell of. S CRISPR/Cas9 delivery platform CRISPR/Cas9 one-time treatments and healthy donors life-transforming medicines Receptor Fusion Enhances. Cash, cash equivalents and marketable securities were $ 600.8 million as of March 31, 2021, Process! Focus on intellia presentations development Outline - Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer resulting in a diverse,... 20, 2021 compared to $ 597.4 million: & quot ; Stock Information Selective advantage MMA... Cash, cash equivalents and marketable securities were $ 600.8 million as of March 31 2021. Ii Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T Cells from NSCLC Patients and donors! Fat-Based molecules that are the basis of Intellia are up 7.15 % in premarket action 24th... < >! To $ 597.4 million to, express or implied statements regarding Intellia & x27.